GlassScriptPhysician profile
Louise T Mann
NPI 1235384397
$2,855.49
in general payments reported to CMS, 2019-2025
33 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $50.21 · 2021: $663 · 2022: $357 · 2023: $573 · 2024: $498 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505 · Education: $32.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,505.03 |
| Education | $32.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $470.91 | 2023-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $312.69 | 2019-2025 | |
| Myovant Sciences INC. | $271.47 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $200.01 | 2021-2024 | |
| Biogen, INC. | $172.52 | 2024-2025 | Zurzuvae |
| Evofem Biosciences, INC. | $133.95 | 2021-2025 | Phexxi, Solosec, Phexx |
| Millicent US INC | $129.30 | 2023-2025 | Femring, Intrarosa, Femlyv |
| Welch Allyn | $114.22 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.16 | 2019-2023 | |
| Astellas Pharma US INC | $104.51 | 2021-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $88.89 | 2022-2024 | |
| Avion Pharmaceuticals | $87.96 | 2019-2022 | |
| Exact Sciences Corporation | $67.75 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $55.82 | 2019 | |
| Organon LLC | $55.57 | 2021-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $54.33 | 2023 | Watchman Flx |
| Aspira Women'S Health INC | $48.72 | 2019-2024 | Ova1 |
| Coopersurgical, INC. | $45.14 | 2022-2025 | Paragard T 380a |
| Ethicon US, LLC | $42.40 | 2022 | |
| Mylan Pharmaceuticals INC. | $36.59 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $34.80 | 2019-2021 | |
| Exeltis, USA INC. | $29.80 | 2021 | |
| Renovia INC | $28.20 | 2019-2020 | |
| Shield Therapeutics INC | $21.99 | 2023 | Accrufer |
| Optumhealth Care Solutions, LLC | $19.77 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Amag Pharmaceuticals, INC. | $18.75 | 2019 | |
| Acessa Health INC. | $18.58 | 2019 | |
| Agile Therapeutics, INC. | $14.64 | 2021 | |
| Currax Pharmaceuticals LLC | $14.43 | 2023 | Contrave |
| Minerva Surgical, INC | $14.14 | 2023 | |
| Gilead Sciences, INC. | $13.79 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.56 | 2019 | |
| Meditrina | $12.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louise Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.